We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.50 | -10.64% | 21.00 | 21.00 | 22.00 | 25.00 | 20.25 | 24.25 | 6,183,038 | 16:40:40 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 1.04M | -21.69M | -0.0832 | -2.58 | 56.02M |
Date | Subject | Author | Discuss |
---|---|---|---|
11/5/2024 13:22 | Yep there's the numbers and dates that have been supplied by the Co. It's binary. Either you trust them, or you don't. Tailor your position accordingly. All the rest is speculation both bull and bear. But I agree it's fun to speculate. | boris cobaka | |
11/5/2024 11:55 | The placing talk isn’t a distraction, it’s reflective of the fact we lost £21m last year and started this year with £15m. Not FORECAST to hit break even until the end of 25. I think it’s very sensible to apply some focus to those points because this is a business, not a science project. It is fair to note they were quite vague where the £6m was coming from, likewise what’s expected next year. Hopefully we get some real traction from here and that’s the way it’s looking, but both AX deals weren’t material to short term revenue, they’re more about the medium - long term POTENTIAL. These things take time. Investors are right to take an interest in the numbers imo. | adw198 | |
11/5/2024 11:20 | And chart-wise The share price bottomed after a few sessions following that 9nov trading update. Have we begun a new uptrend of higher highs, higher lows? The share price tagged 11.5 in the inevitable pullback after the super spike, so if we're beginning the run up to the next higher high it's likely to be some move... I'd say the weekly 200dma is pretty much nailed on. Around the low 60's, however I'd expect some major volatility on the way. How soon? It's a long way from here but the recent rns' have contributed to the gradual momentum building here. The talk of placings etc is a distraction from what's really going on and yep at some point they may need to go to the market but not necessarily. If income flatlines then I'd be looking at third quarter this year but that's a long way off. Wall of worry - some perhaps are genuinely worried and some are obviously fake. That's thing in these situations, recency bias will cloud judgement, but I could see that switch to fomo very quickly and this may already be in the early stages. After the massively disappointing reaction to the FDA approval (after that lovely spike) it's been death by a thousand cuts. It can take some time before that former mindset is shaken off but jmo it's begun. Gla Lth's, n' pesky traders. Oh and placing experts of which there are many... | boris cobaka | |
11/5/2024 10:07 | Morning Anglers! From the Jan super spike rns - 4) Actionable variants identified in our patient cohort in the CTCs that were not present in the ctDNA included variants targeted by widely used drugs from many large pharma companies, for example: · PIK3CA (E545K): Alpelisib (Piqray®) marketed by Novartis · EGFR (T790M): Tagrisso (Osimertinib®) marketed by Astra Zeneca · ESR1 (K303R): Elacestrant (Oserdu®) marketed by Menarini · MTOR (T1977K): Everolimus (Afinitor®) marketed by Novartis · ERBB2 (R678Q): Trastuzumab, Pertuzumab, Neratinib, Afatinib marketed respectively by Astra Zeneca, Roche Genentech, Puma Biotechnology, and Boehringer Ingelheim Maybe a few took notice. | boris cobaka | |
11/5/2024 08:54 | Morning Nigel Fair summary and yes I acknowledged they’ll be things we’ve not heard about, we just don’t have alot to go on to tell us whether they’re on track. @krpyton they lost £21m in 2023 and the savings were forecast to reduce costs by £3m. So that would be circa £18m loss this year, with a starting cash pile of £15m. So you tell me how cash will last till Q2 without considering revenue? | adw198 | |
11/5/2024 08:46 | We’ve had a $250k deal, a £150k deal and the £500k deal with AZ that complete Q1 25. That's what they've disclosed in RNS. There will be other things and also worth notng from Nov 23 RNS there weresales secured in 2023 that will be recognised in 2024: The Company expects revenue recognised for 2023 will be c. £2.2 million, which is an increase of 120% over revenue achieved in 2022 but below current market consensus of c. £3.0 million. New sales secured in 2023 are expected to be c. £3.3 million however revenue recognition for some of these sales will fall into the 2024 financial year. It's clearly taking longer than expected to build revenue and there will likely need to be another fundraise but it's about momentum and the quality of customers they are building. | nigelpm | |
11/5/2024 08:43 | @krypton Are you really claiming the cash runway projection doesn’t consider revenue? That would be a weird way of budgeting! | adw198 | |
11/5/2024 08:36 | "Gross margin for H2 is expected to be higher than H1 reflecting the product-service mix and, together with tight cost control, to result in the cash position at 2023 year end being in line with consensus at c. £15 million." "The cost savings from the streamlining of our clinical services business will now extend the forecast cash runway into Q2 2025" £15m in cash is expected to last until Q2 2025. This has nothing to do with revenues. The cash they had end of 2023 will last until Q2 2025 Can't make it any clearer for those too thick to understand sent from my iPhone | kryptonsnake | |
11/5/2024 08:22 | @hoohah In November they guided the market they expected to triple revenue to £6m. Based on that massive growth projection they forecast cash lasting till Q2 25. Some of us are concerned whether we’re on track to achieve £6m because there’s no evidence to suggest that. We’ve had a $250k deal, a £150k deal and the £500k deal with AZ that complete Q1 25. Fair enough we don’t what else is being achieved that they haven’t announced and that’s particularly true of product sales but at the very least it’s a risk. If they aren’t on track and need to guide the market the results will be the time to do it. Those results are strangely later than previous which might suggest a placing will be announced around the same time. A placing isn’t the end of the world and I personally will almost certainly buy back in after it arrives because for me it de risks the prospects here. But it would most likely lead to a drop in the share price Bones knows this very well because it’s the kind of analysis he applies to some of the many other message boards he slates other shares on. He just happens to want to pump the price here which is why he’s so aggressive to anyone who doesn’t play along with his agenda. What he’s admitted is he sold in January the exact time he was posting regularly about how great things were. Yet he’s also announced he hasn’t sold a penny. Even if the above results / placing does play out it’s also possible there could be a stonking deal announced any time to send the share price much higher. That’s fine with me, we also have to make our own decisions and live with the consequences. I watched RENE go to nothing from a similar position so just want to manage my risk. Results will be in the next 2 weeks so the good news is we’ll be finding out very soon. | adw198 | |
11/5/2024 08:08 | ESMO breastcancerconferen Update to coincide? | fhmktg | |
11/5/2024 07:32 | Washingmachine, they have already informed the market what results look like back in November, so should be no surprises and future outlook and projections commentary will be main point of interesthTTps://uk.a | hoorah henry | |
11/5/2024 07:22 | Add POLX to that list You can all read, make your own mind up on this character. Don’t be fooled on here | washingmachine | |
11/5/2024 07:16 | Bones you are on at least five other threads / components talking about placings GDR being your latest today, Talk about pot kettle black. AGL will announce a placing, coinciding with the next results The results will miss projected forecast of 6 million Pretty odvious, what’s more obvious is that the Shareprice will retreat No matter your constant barrage of posters having a truthful opinion That clearly doesn’t fit your agenda of the time Especially your new found devotion of everything Andrew Newland You are a very manipulative poster, very similar traits to Pwhite Who’s coming very unstuck on VRS ! | washingmachine | |
10/5/2024 22:09 | Timberrrrrr Any bag holders raise your hands ! | havinthelasttoast | |
10/5/2024 18:51 | So much noise, but welcome to see some progress with further collaborations ahead. Short of a takeover (not impossible) happy to see them get embedding as a companion diagnostic. A bit daft having to test against each and every one but so says the FDA.. Back into hiding. Much too noisy with traders for my liking. | waterloo01 | |
10/5/2024 18:19 | Heading back to 12p lol! | bones699 | |
10/5/2024 18:19 | 10p for the company that's overpriced I want a discount! | bones699 | |
10/5/2024 17:24 | Pump and dump over then now? Placing anyone. 10p ? | havinthelasttoast | |
10/5/2024 16:38 | Those were the sells that spiked thus lower at 2.30 around 780k | boris cobaka | |
10/5/2024 16:25 | Looks like my leftover toast wasn't AN likeness after all dammit. Elmo again. | boris cobaka | |
10/5/2024 16:23 | 699 says buy (secretly) | muffster | |
10/5/2024 16:21 | Yes same time as the 4x100k.blocks buys went through too. Tr1 coming perhaps they have held this down today filling an order | bones698 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions